Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting

Core Insights - Sera Prognostics, Inc. announced that the results of the PRIME study will be presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting on January 31, 2025 [1][2] - The PRIME study evaluated the effectiveness of the PreTRM test in identifying pregnant women at higher risk of preterm delivery and its impact on neonatal outcomes [2][4] - The PreTRM test is a blood-based biomarker test that provides individualized risk predictions for spontaneous preterm birth [6] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through innovative diagnostic tests aimed at early prediction of preterm birth risk [4] - The company is headquartered in Salt Lake City, Utah, and focuses on precision pregnancy care to reduce healthcare delivery costs [4] Study Details - The PRIME study, which stands for Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outcomes, achieved at least one primary endpoint at the required statistical significance level during its interim analysis [2] - The study's enrollment was halted in December 2023, and the company has since concentrated on data gathering and analysis for the complete cohort [2] Industry Context - Preterm birth is defined as any birth before 37 weeks' gestation and is a leading cause of illness and death in newborns [5] - The March of Dimes Report Card indicates that over 10% of infants in the U.S. are born prematurely, with significant long-term medical complications associated with prematurity [5] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5]